Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Neurology

Neurology

FULL SPECTRUM OF NEUROLOGICAL DISEASE TESTING

A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories. Our highly specialized neurology testing menu features more than 400 neurologist-backed assays to evaluate the simplest to most complex cases. From analyses for Alzheimer’s disease and dementia to targeted antibody detection for autoimmune neurology conditions, our robust testing library provides partners with results that move solutions through the development pipeline.

With 19 subspecialty labs that perform testing, we are at the forefront of research that integrates novel biomarker discoveries into our evaluations. Our clinical experience gives us the expertise to develop tests that deliver actionable answers.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Biopharma only testing Biopharma only testing
Biopharma only testing

Our BioPharma Diagnostics-specific neurology testing is designed to provide answers for your patients.

Full suite of neurology testing Full suite of neurology testing
Full suite of neurology testing

Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.

Dementia Dementia
Dementia

Offering the industry’s most sophisticated suite of testing available, including biomarker evaluations, autoimmune panels, testing for rapidly progressive cases, and an innovative combination assay, Mayo Clinic Laboratories is a one-stop laboratory solution for dementia and Alzheimer’s disease testing.

Demyelinating disease Demyelinating disease
Demyelinating disease

Driven by ongoing research into the presence of antibody biomarkers in patients with immune-mediated demyelinating neuropathy, Mayo Clinic Laboratories has developed several unique, highly accurate assays that use pioneering methods to identify specific biomarkers associated with the harmful immune response. Order these tests when nerve conduction studies show prolonged distal latency or marked slowing of conduction velocities.

Epilepsy Epilepsy
Epilepsy

Proper identification of immune-mediated epilepsy is vital to directing appropriate treatment. Our autoimmune epilepsy evaluation detects for more than a dozen antibody biomarkers related to autoimmune causes.

Mitochondrial disease Mitochondrial disease
Mitochondrial disease

We offer four molecular test options that can complement radiological and histological evaluations to confirm a mitochondrial diagnosis and identify a specific mitochondrial syndrome. Rather than a series of targeted panels or single-gene analysis, we recommend sequencing the entire mitochondrial genome and/or performing a comprehensive nuclear gene panel.

Movement disorders Movement disorders
Movement disorders

Our comprehensive autoimmune movement disorders panel is continuously updated to include newly discovered antibody biomarkers and uses advanced testing approaches to detect actionable antibodies. Data-backed and developed by our autoimmune neurology experts, our evaluations include detection of several antibody biomarkers available only at Mayo Clinic Laboratories.

Neuromuscular disorders Neuromuscular disorders
Neuromuscular disorders

Our distinctive approach to testing for genetic neuromuscular disorders uses phenotypic information to streamline diagnosis. Phenotype-specific panels enable targeted testing, improving diagnosis and minimizing uncertain results.

Peripheral neuropathy Peripheral neuropathy
Peripheral neuropathy

Our hereditary peripheral neuropathy test menu includes both comprehensive and targeted NGS panels to assist in identifying genetic causes across the spectrum of peripheral neuropathies.

Sleep disorders Sleep disorders
Sleep disorders

Our testing to assess for narcolepsy evaluates for low concentrations of orexin-A/hypocretin-1 in cerebrospinal fluid. Sensitive and specific, this evaluation provides results that can guide appropriate treatment for patients.

Neurology testing overview

The rapid expansion of neurology testing has resulted in the discovery of increasing numbers of clinically relevant biomarkers. Mayo Clinic Laboratories collaborates closely with the clinical practice to develop and offer advanced testing — much of which is unavailable anywhere else — to address the most difficult questions.

Our laboratories are led by board-certified clinical neurologists and clinical chemists who have extensive experience using testing to guide patient care. These experts are available for consultations on test selection and results interpretation. Our physicians are committed to research and discovery to pave the way for the future of neurology testing.

Comprehensive disease testing

A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories, including: 

  • Alzheimer's disease
  • Demyelinating disease
  • Epilepsy
  • Mitochondrial disease
  • Movement disorders
  • Neuromuscular disorders
  • Peripheral neuropathy
  • Sleep disorders
News and updates

The latest

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

Learn more
Small Fiber Neuropathy: Diagnosis and Treatment

This “Specialty Testing” webinar will discuss the considerations physicians must weigh when evaluating suspected neuropathy patients with special emphasis put on small-fiber neuropathy and the most appropriate laboratory testing related to that phenotype.

Study can improve understanding of how disability develops in MS

Mayo Clinic researchers have identified clear differences in brain and spinal cord scarring in patients with demyelinating diseases.

An uncommon antibody, a life restored: Jori Pearson

Sophisticated laboratory testing solved a medical riddle and finally got Jori Pearson back on his feet, doing what he loves.

Multiple Sclerosis Profile Updates

Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional oligoclonal banding, enabling definitive answers for the challenging diagnosis.

Mayo Clinic develops and validates new antibody test to diagnose multiple sclerosis

Mayo Clinic researchers have developed and validated a new antibody test to diagnose multiple sclerosis (MS). The new test is an automated and cost-effective method compared to other tests used to diagnose MS, according to the research published in Mayo Clinic Proceedings. The test is now available through Mayo Clinic Laboratories.

Stiff-Person/PERM Evaluation

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' stiff-person assay provides comprehensive evaluation for individuals on the spectrum of stiff-person syndrome. In addition to guiding treatment decisions, the assay can help confirm the most-severe stiff-person phenotype — known as PERM — which is associated with potential cancers.

A downward spiral undone: Jon Bratsch

Lying in an ICU bed as sick as he could get, Jon Bratsch thought he was past the point of no return. But when a Mayo Clinic Laboratories’ test revealed the source of his dire symptoms, everything changed. Today, Jon’s back to the life and family he loves.

Reclaiming her joy: Joy Carol

A tenacious fighter, Joy Carol never lost hope that a mysterious condition that had stripped her of her ability to move would be identified. Hope turned into reality when a Mayo Clinic Laboratories test identified the cause of her illness and opened the door to successful treatment.

Back from the brink: Sheila Lewis

Mayo Clinic Laboratories’ comprehensive approach to targeted antibody testing played a crucial and lifesaving role in moving Sheila Lewis to recovery from autoimmune encephalitis.

Autoimmune Axonal Evaluation

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.

Epic journey yields unique offering

The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.

Glimmer of Hope: Gregor Heinrich

While Gregor Heinrich never could have imagined that testicular cancer was related to his problems with his vision and gait, learning he was positive for KLHL11 protein biomarkers meant he could receive treatment for both the cancer and the illness behind it.

View More
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.